Despite major advances in targeted therapies, immunotherapies, and combination regimens, therapy resistance remains a central barrier to durable cancer ...

The human immune system is finely tuned to detect and destroy viral threats. But this same defense system can misfire. When ...

A high-resolution proteomic landscape of minor glomerular abnormalities (MGAs) is established via pressure cycling technology ...

At AACR 2026, the Genialis™ Supermodel–powered RNA survival model outperforms standard of care in real-world clinical data, establishing a scalable biomarker framework for ADC drug developmentBOSTON-- ...

The Damon Runyon Cancer Research Foundation has named 13 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading ...

Researchers at The University of Texas MD Anderson Cancer Center have identified an epigenetic target for replication stress, ...

Tick-borne encephalitis virus, known as TBEV, hijacks the internal membrane machinery of host cells to build hidden factories ...

By John Vandermosten, CFA NASDAQ: CRDF Key Opinion Leader Event Places Onvansertib in Context Cardiff Oncology, Inc. (NASDAQ: ...

Artios Pharma collected $115 million from an oversubscribed series D that will support its growing ambitions for its pipeline of DNA damage response (DDR)-targeting cancer prospects. The biotech is ...

The role of prolactin (PRL) in breast cancer and its role within the context of the tumor microenvironment are not well understood. In our previous study, we demonstrated a cross-talk between the ...